Opiant Pharmaceuticals, Inc.
Rigrodsky Law, P.A. is investigating Opiant Pharmaceuticals, Inc. (“Opiant”) regarding possible breaches of fiduciary duties and other violations of law related to Opiant’s agreement to be acquired by Indivior PLC. Under the terms of the agreement, Opiant’s shareholders will receive $20.00 per share plus up to $8.00 per share in contingent value rights.